Some recent papers have focused on the activity of imatinib-mesylate, a selective inhibitor of tyrosine kinase, in idiopathic hypereosinophilic syndrome (HES) [1], [2], [3] and [4]. In this setting, a possible therapeutic target was identified by Cools et al. [2], who described the fusion tyrosine-kinase gene FIP1L1/PDGFRA as the result of an interstitial deletion within chromosome 4 in nine out of sixteen (56%) patients affected by HES. Of interest, although in this study the response to imatinib was strictly correlated with the presence of FIP1L1/PDGFRA rearrangement (all patients with such a molecular lesion treated with imatinib responded), only five out of nine responding patients evidenced the abnormal transcript [2]. Among the possible alternative mechanisms for the activation of the PDGFRA tyrosine-kinase domain, these authors suggested there may be a different fusion gene.

Musto, P., Perla, G., Minervini, M., Carella, A., LO COCO, F., Catalano, G. (2004). Imatinib-mesylate for all patients with hypereosinophilic syndrome?. LEUKEMIA RESEARCH, 28(7), 773-774 [10.1016/j.leukres.2003.11.014].

Imatinib-mesylate for all patients with hypereosinophilic syndrome?

LO COCO, FRANCESCO;CATALANO, GIANFRANCO
2004-07-01

Abstract

Some recent papers have focused on the activity of imatinib-mesylate, a selective inhibitor of tyrosine kinase, in idiopathic hypereosinophilic syndrome (HES) [1], [2], [3] and [4]. In this setting, a possible therapeutic target was identified by Cools et al. [2], who described the fusion tyrosine-kinase gene FIP1L1/PDGFRA as the result of an interstitial deletion within chromosome 4 in nine out of sixteen (56%) patients affected by HES. Of interest, although in this study the response to imatinib was strictly correlated with the presence of FIP1L1/PDGFRA rearrangement (all patients with such a molecular lesion treated with imatinib responded), only five out of nine responding patients evidenced the abnormal transcript [2]. Among the possible alternative mechanisms for the activation of the PDGFRA tyrosine-kinase domain, these authors suggested there may be a different fusion gene.
lug-2004
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/15 - MALATTIE DEL SANGUE
English
Con Impact Factor ISI
Piperazines; Pyrimidines; Chromosomes, Human, Pair 2; Hypereosinophilic Syndrome; Humans; Middle Aged; Translocation, Genetic; Male; Genetic Heterogeneity; Chromosomes, Human, Pair 4; Remission Induction
Musto, P., Perla, G., Minervini, M., Carella, A., LO COCO, F., Catalano, G. (2004). Imatinib-mesylate for all patients with hypereosinophilic syndrome?. LEUKEMIA RESEARCH, 28(7), 773-774 [10.1016/j.leukres.2003.11.014].
Musto, P; Perla, G; Minervini, M; Carella, A; LO COCO, F; Catalano, G
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
imatinib-mesilate in all patients with HS.pdf

accesso aperto

Descrizione: articolo
Dimensione 78.43 kB
Formato Adobe PDF
78.43 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/49148
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 7
social impact